CiteSpace bibliometric analysis of safety and risk studies of antibody drugs in China
10.12173/j.issn.1008-049X.202311109
- VernacularTitle:国内抗体药物安全性及风险研究的CiteSpace文献计量分析
- Author:
Yue PENG
1
,
2
;
Lingling LIU
;
Yuanxuan CAI
;
Yuhang ZHAO
;
Xiaofang SHANGGUAN
;
Kangling LI
;
Zherui CHEN
;
Ke LI
;
Rui HUANG
;
Yuanyuan LU
Author Information
1. 武汉科技大学医学院药学系(武汉 430065)
2. 湖北省妇幼保健院药学部(武汉 430070)
- Keywords:
Antibody drugs;
CiteSpace;
Safety;
Risk;
Adverse reactions;
Bibliometrics;
Drug safety;
Risk management
- From:
China Pharmacist
2024;27(6):1019-1027
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the domestic antibody drug safety and risk research status,the latest research hotspots and frontiers in the current ten years.Methods CiteSpace 6.2.R2 software was used to analyze all literature related to the safety and risk of antibody drugs in CNKI,WanFang data and Vip database from 2012 to 2022.Results A total of 2 773 pieces of literature were obtained from the three databases,which were imported into CiteSpace after deduplication,and finally,1 870 pieces were included in the analysis.In the past decade,the number of articles published in the field of antibody drugs safety and risk research has remained at about 100 articles per year from 2012 to 2019,since 2020,the number of articles published has started to increase,and the annual number of articles published has increased to around 300 articles from 2021 to 2022.The network graph of domestic institutional cooperation showed that there was a lack of cooperation among the research institutions of antibody drug safety and risk research,mainly due to the fact that hospitals were conducting research in this field,and the types of research subjects were relatively single.The author collaboration network graph showed that the core teams in this research field,such as Li Bo,Yang Yanwei,and Lin Zhi,had the closest collaboration,while there was less collaboration among high-yield authors,additionally,some experts and scholars conducted research on their own as individuals or small groups,the research focused on adverse reactions,safety,bevacizumab,Rituximab,Meta-analysis,etc.Conclusion In the past decade,domestic research has mainly focused on the clinical efficacy and safety of antibody drugs,with few scholars exploring the risk of antibody drugs,therefore,in the future,it is necessary to pay attention to the research on the risks of antibody drugs.
